Regeneron is a biotechnology company that develops and commercializes medicines for the treatment of metabolic, inflammatory and infectious diseases.
Read morePresident & CEO
Leonard S. Schleifer
Annual Revenue
$14B
Regeneron's revenue is the ranked 19th among it's top 10 competitors. The top 10 competitors average 36B. Over the last four quarters, Regeneron's revenue has decreased by 42.3%. Specifically, in Q1 2022's revenue was $3B; in Q4 2021, it was $2.4B; in Q3 2021, it was $3.5B; in Q2 2021, Regeneron's revenue was $5.1B.